Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (9): 6-10.doi: 10.6040/j.issn.1671-7554.0.2018.535

Previous Articles    

Recombinant human vascular endostatin enhances antitumour activity of EGFR-TKIs for lung cancer

SHI Shuyuan1, GUAN Zhiyu1, SUN Daqiang2   

  1. 1. Department of Thoracic Surgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, China;
    2. Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300051, China
  • Published:2022-09-27

PDF (PC)

15

Abstract: Objective To study the inhibitory effect of recombinant human vascular endostatin(endostar)combined with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), erlotinib, on the resistant cell lines of EGFR-TKIs H1975(with L858R and T790M)in vitro and in vivo. Methods The cell activity of H1975 cell line was detected, and the absorbance values of erlotinib, endostar and erlotinib + endostar were determined. The xenograft tumor model of H1975 lung cancer cell line was established, and the nude mice were randomly divided into 4 groups(control group, erlotinib group, endostar group and combined medication group), 6 in each group. The tumor diameter was measured once every 3 days since the administration of the drug, and all the experimental mice were executed 2 weeks later. The tumors were taken out, measured and photographed. Results Cell experiments in vitro showed that, erlotinib had a statistically significant inhibitory effect on H1975 cell proliferation(P=0.043), while endostar had no statistically significant inhibitory effect on H1975 cell proliferation(P=0.261). The effect of erlotinib + endostar coincided with erlotinib. The animal experiments in vivo showed that, endostar could not inhibit the tumor cell growth(P= 山 东 大 学 学 报 (医 学 版)56卷9期 -石树远,等.重组人血管内皮抑素增强EGFR-TKIs对肺癌的抗瘤作用 \=-0.112), and erlotinib could inhibit the tumor cell growth (P=0.018). Meanwhile, the two drugs exhibited a synergistic effect(P=0.048). Further pairwise comparison showed statistically significant differences between the combined medication group and control group/erlotinib group(P=0.046, P=0.023). Conclusion Endostar combined with erlotinib can enhance antitumour activity of erlotinib for lung cancer and reverse the T790M-related drug resistance. Endostar combined with erlotinib has a promising application prospect for patients with EGFR-TKIs resistance.

Key words: Recombinant human vascular endostatin, Epidermal growth factor receptor tyrosine kinase inhibitor, Resistant

CLC Number: 

  • R734.2
[1] Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013:an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1): 1-10.
[2] 黄受方.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会国际多学科肺腺癌分类(2011年版)解读[J].中华病理学杂志,2011, 40(12): 793-796.
[3] Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-Mainland China subset analysis of the PIONEER study[J]. PLoS One, 2015, 10(11): e0143515. doi: 10.1371/journal.pone.0143515.
[4] Li H, Zhou S, Li X, et al. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines[J] Cancer Biother Radiopharm, 2013, 28(2): 115-123.
[5] Wang S, Song Y, Yan F, et al. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors[J]. Front Med, 2016, 10(4): 1-6.
[6] Rolff J, Becker M, Merk J, et al. Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts[J]. Targeted Oncology, 2016, 90(4): 1-8.
[7] Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2): a randomised, double-blind trial[J]. Lancet Oncology, 2013, 14(8): 777-786.
[8] Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth gactor receptor mutations[J]. J Clin Oncol, 2016, 34(27): 3258-3266.
[9] Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer[J]. Clinical Lung Cancer, 2007, 2: 79-85.
[10] Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy[J]. Clin Cancer Res, 2006, 12(7 Pt 1): 2197-2207.
[11] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7): 629-640.
[12] 袁冬梅,宋勇.表皮生长因子受体敏感突变阳性晚期非小细胞肺癌内科一线治疗的精准化[J].中华肿瘤杂志, 2017, 39(2): 98-101. YUAN Dongmei, SONG Yong. Precision first line therapy for advanced non small cell lung cancer patients harboring EGFR mutation[J]. Chin J Oncol, 2017, 39(2): 98-101.
[13] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674.
[14] Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity[J]. Nat Rev Cancer, 2008, 8(8): 579-591.
[15] Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors [J]. Nat Med, 2003, 9(6): 669-676.
[16] Tan H, Mu G, Zhu W, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug[J]. Biol Pharm Bull, 2011, 34(4): 545-550.
[17] Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor(EGFR)blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance[J]. Clin Cancer Res, 2009, 15(10): 3484-3494.
[18] Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J]. PLoS One, 2012, 7(4): e34646. doi: 10.1371/journal.pone.0034646.
[19] Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases[J]. Nat Rev Drug Discov, 2011, 10(6): 417-427.
[20] Welti J, Loges S, Dimmeler S, et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer[J]. J Clin Invest, 2013, 123(8): 3190-3200.
[21] Zhu JQ, Zhong WZ, Zhang GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals[J]. Cancer Lett, 2008, 265(2): 307-317.
[22] Ning T, Jiang M, Peng Q, et al. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model[J]. Thorac Cancer, 2012, 3(3): 229-238.
[23] Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J]. Eur J Cancer, 2017, 84: 184-192. doi: 10.1016/j.ejca.2017.07.037.
[24] Peng H, Zhang Q, Li J, et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma[J]. Oncotarget, 2016, 7(13): 17220-17229.
[25] Pallaud C, Reck M, Juhasz E, et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer[J]. Lung Cancer, 2014, 86(1): 67-72.
[26] 贾丽君,任宏涛,黄珊,等.厄洛替尼联合贝伐单抗一线治疗晚期非小细胞肺癌的疗效观察[J]. 陕西医学杂志, 2016, 45(4): 492-493.
[27] 熊德明,贾茜,李刚,等.厄洛替尼联合贝伐单抗治疗晚期非小细胞肺癌的临床观察[J].中国现代医药杂志, 2013, 15(4): 7-9. XIONG Deming, JIA Qian, LI Gang, et al. Clinical observation of combined erlotinib with bevacizumab in advanced non-small cell lung cancer patients[J]. Modern Medicine Journal of China, 2013, 15(4): 7-9.
[28] Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567): an open-label, randomised, multicentre, phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1236-1244.
[29] 王慧娟,张国伟,王启鸣,等.吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究[J]. 实用临床医药杂志, 2012, 16(21): 16-18. WANG Huijuan, ZHANG Guowei,WANG qiming, et al. Clinical study on the relief treatment of the combined recombinant human endostatin after failed treatment of gefitinib for advanced non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2012, 16(21): 16-18.
[1] LI Xiaofei, HUANG Shan, OUYANG Bing, YU Tingting, LIANG Guiliang, WANG Lin. Applicative value of gene Xpert MTB/RIF for the rapid detection of pulmonary tuberculosis in the clinical pathway [J]. Journal of Shandong University (Health Sciences), 2018, 56(6): 35-40.
[2] YANG Xiaxin, MENG Mingzhu, JI Kunqian, WANG Xiaotang, TONG Lili, WANG Aiqin, ZHAO Xiuhe. Clinical features of epilepsic seizures in patients with MELAS [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 74-80.
[3] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[4] LI An, CHEN Fengzhe, WANG Zheng, MENG Xiangzhu, XU Nannan, MA Lixian. In vitro synergy testing of sitafloxacin, cefoperazone-sulbactam and polymyxin E against extensively drug-resistant Acinetobacter baumannii [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 82-85.
[5] HAN Bo, QI Mei, TAN Weiwei, YANG Muyi. Castration-resistant prostate cancer: current understanding of mechanisms and emerging novel agents [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 1-7.
[6] YAN Bing1, LIU Guoqin2, JIANG Yongsheng2, SHEN Haiyu2, SUN Shaochuan2. Establishment of cisplatin-resistant gastric cancer cell line and the biological characteristics [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 49-52.
[7] ZHANG Miaoci, LI Ping, HA Minwin. Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 55-59.
[8] GUO Ai-ping1, YU Xiu-juan2, LIU Xin-feng1, WANG De-jing1, ZHENG Wen1. Distribution and antibiotic resistance of 3598 clinic isolated pathogenic bacteria [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 87-91.
[9] ZHANG Jia-sheng1, SUN Qiang1, BIAN Xue-feng1,2, YAN Yun1, LI Wen-jing1, LI Ren-zhong3, CHEN Cheng3, ZHANG Hui3. Management and flow direction of multi-drug resistant tuberculosis  patients discharged from TB hospitals [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(2): 125-.
[10] MENG Yan1, CHEN Liyong2, XU Guifa1. Effects of resistant starch on intestinal function and aberrant crypt foci during the development of rat colorectal cancer induced by  Azoxymethane [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 23-26.
[11] LIU Bin, XU Guifa， HAN Wenting， LIU Ruiping
. The resistant starch contents of Luohanshen [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 103-105.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd